– USA, CA – RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company today announced the appointment of Lori Lyons-Williams to its Board as as an Independent Director.
“We are very excited to welcome Lori to RAPT’s board of directors,” said CEo, Dr. Brian Wong. “Her strong track record of driving strategic and commercial success across both biotech and pharmaceutical products will be invaluable as we continue to advance our pipeline of promising inflammation and oncology product candidates.”
About Lori Lyons-Williams
Ms. Lyons-Williams is President and COO at Neumora Therapeutics, a clinical-stage biotechnology company pioneering precision medicines for brain diseases. In her current role, Ms. Lyons-Williams is responsible for research and development, external affairs, CMC/manufacturing, program management, and new product planning. Before Neumora, she served as Chief Commercial Officer of Dermira, publicly-traded biotech focused on medical dermatology including atopic dermatitis, until its acquisition. Previously, as VP of Sales and Marketing at Allergan, Lori built an emerging neurotoxin franchise, successfully launched multiple products, and expanded the pipeline through external collaborations and strategic transactions. Lori currently serves as an independent director on the board of Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration. She was previously an independent director on the board of Five Prime Therapeutics, a clinical-stage biotech focused on the discovery and development of protein therapeutics in immuno-oncology, until its acquisition.
“I see the potential of RAPT’s pipeline to meaningfully improve the lives of people living with inflammatory disease and cancer, and I am particularly encouraged by the broad opportunity for RPT193 in atopic dermatitis and allergic diseases given my prior experience in these therapeutic areas. As RPT193 and FLX475 continue to progress, I look forward to collaborating with the RAPT management team and board members as we work to advance the company and these novel candidates which have shown initial clinical promise,” commented Lori Lyons-Williams.
Ms. Lyons-Williams holds an MBA from the Carlson School of Management at the University of Minnesota and a BA from Virginia Tech. She is a member of Executive Women in Bio’s Boardroom Ready, an executive leadership program working to diversify life science corporate boards by championing women from the C-suite to the boardroom.
About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, RPT193 and FLX475, each targeting C-C motif chemokine receptor 4, for the treatment of inflammation and cancer, respectively. The Company is also pursuing a range of targets that are in the discovery stage of development.
For more information: https://rapt.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
